Company profile: Nexus BioPharma
1.1 - Company Overview
Company description
- Provider of preclinical-stage biotechnology research and development focused on developing new therapies and intellectual property.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Nexus BioPharma
Inozyme Pharma
HQ: United States
Website
- Description: Provider of therapies for rare diseases of calcification affecting soft tissues and bone, including a clinical-stage enzyme therapy (INZ-701) for pathologic mineralization and intimal proliferation in ENPP1 Deficiency, ABCC6 Deficiency, and calciphylaxis. Conducts clinical trials, offers a genetic testing process for ENPP1 Deficiency, and provides patient and family support and community resources.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Inozyme Pharma company profile →
Millendo Therapeutics
HQ: United States
Website
- Description: Provider of biopharmaceutical research and development, previously primarily focused on developing novel treatments for endocrine diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Millendo Therapeutics company profile →
Nimbus Therapeutics
HQ: United States
Website
- Description: Provider of computational drug discovery solutions using a platform that applies computational chemistry and structural biology to design selective small molecule therapeutics targeting disease-related proteins. Offerings include TYK2 and HPK1 inhibitors, AMPK activators, and ACC inhibitors for immune, metabolic, and liver disease indications such as psoriasis and NASH.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Nimbus Therapeutics company profile →
Inversago Pharma
HQ: Canada
Website
- Description: Provider of clinical-stage biotech therapies based on peripherally-acting CB1 inverse agonists, including INV-202, a small molecule CB1 receptor blocker for metabolic disorders in Phase 2 studies for diabetic kidney disease and obesity, and INV-347, a next-generation oral CB1 receptor blocker in Phase 1 evaluating safety, tolerability, and pharmacokinetics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Inversago Pharma company profile →
Calliditas Therapeutics
HQ: Sweden
Website
- Description: Provider of specialty pharmaceuticals for unmet medical needs in niche indications, including TARPEYO (delayed-release budesonide for renal diseases), Kinpeygo (renal and hepatic diseases), NEFECON (candidate for primary IgA nephropathy), and Setanaxib (NOX1/4 inhibitor in trials for PBC and head & neck cancer), plus pipeline development for orphan renal/hepatic diseases and strategic partnerships for development and commercialization.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Calliditas Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Nexus BioPharma
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Nexus BioPharma
2.2 - Growth funds investing in similar companies to Nexus BioPharma
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Nexus BioPharma
4.2 - Public trading comparable groups for Nexus BioPharma
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →